Generated by AI
Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis. The company’s lead program, IMU-838, is being studied in late-stage and mid-stage clinical development, while IMU-856 is being advanced for gastrointestinal disorders linked to intestinal barrier dysfunction. Immunic also maintains earlier-stage research programs in immune-mediated diseases. With operations in the United States and Germany, Immunic, Inc. plays a role in the clinical-stage biopharmaceutical market by advancing oral, mechanism-based therapies aimed at complex inflammatory conditions.
Website1200 Avenue of the Americas
New York, NY, 10036
United States
The latest articles about IMUX.
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November:
Summary of Nov 17's posts. Generated by AI.
Summary of Feb 27's posts. Generated by AI.
Summary of Feb 13's posts. Generated by AI.
Investors talking about IMUX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.